Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

pound, Traficet-EN(R), is in a Phase II/III clinical trial in patients with moderate-to-severe Crohn's disease. Outside the GSK alliance, the company has a third clinical asset in development, a proprietary CCR2 inhibitor in Phase I clinical trials, as well as a number of late-stage preclinical programs.

About Rheumatoid Arthritis and CCX354

Rheumatoid arthritis (RA) is a chronic and debilitating inflammatory disease which causes pain, stiffness, swelling and limitation in the motion and function of multiple joints. RA is estimated to affect more than two million people in the U.S. and is a leading cause of work disability. The exact cause of RA is unknown, but is believed to be the body's immune system attacking the synovium, the tissue that lines the joints. More than three million Americans suffer from RA. Although therapy has improved dramatically over the last 25 years, there is still no single therapy that is effective for all patients. Treatment of RA can be divided into Disease-Modifying Antirheumatic Drugs (DMARDs), anti-inflammatory agents and analgesics, addressing a $10 billion market.

During the development and progression of RA, the recruitment of immune cells, both innate and adaptive, into affected joints plays a key role in the inflammatory process and the ensuing joint destruction. There is strong evidence implicating CCR1 in the pathology of RA. ChemoCentryx's approach to specifically target the CCR1 receptor with CCX354 represents a new mechanism of action in the potential treatment of RA.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammat
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the company ... 2010 , after the market closes. The press release will be followed by ... to the public via telephone and webcast. During the conference call, the company ... , , ...
... RIVER, N.Y. , April 26 Netsmart Technologies, Inc., ... human services organizations, today named Lakeside Behavioral Healthcare of Orange ... Customer Innovation Award. , ... The Netsmart Customer Innovation Award recognizes organizations for their ...
Cached Medicine Technology:Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 3Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 4Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 5
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at the ... July 17 in Copenhagen, Denmark. Data from the ... transition from cognitive normality to mild cognitive impairment and ... Aging Study , established in 1980 to examine healthy ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... City, July 9, 2014 A study published in ... De Koninck and Robert Bonin, two researchers at Universit ... hypersensitivity using a new method that involves rekindling pain ... could lead to novel means to alleviate chronic pain. ... Universit Laval and Institut universitaire en sant mentale de ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... -- an antibiotic being prescribed to people who may ... growth when taken by pregnant women. Instead, the Centers ... Cipro to pregnant women. The recommendation comes as health ... general population, possibly causing common bacteria to become resistant ...
... study, a trial of a new anti-cancer drug interacts ... a natural product, is being tested as an anti-cancer treatment. ... of the drug on the genes that are activated in ... affected by ceflatonin. These experiments have been done in human ...
... advertisements of prescription drugs, statements about drug benefits ... quantify the medications' expected benefit; instead, they make ... Medical School, Hanover, New Hampshire. // ... is that the medicine is going to prevent ...
... warn that gout can be incredibly painful, and if not ... belief, gout can strike at any time, and for no ... rich food and wine, and women can be affected too, ... affect middle-aged men and some people find an attack follows ...
... pregnant women at risk of the potentially fatal condition ... and E. ,The study, published in the Lancet, found ... pre-eclampsia. ,The condition involves the pregnant mother with ... of the unborn child through the placenta. ,Between ...
... who snore when they are pregnant may be at risk ... lives when they give birth. Around 10% of pregnant women ... can lead to injury or even death in the mother ... pressure by resting or with medication. But drugs may put ...
Cached Medicine News:Health News:Snoring could be a warning 2
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
Shielding's Wrap-Around / Back Relief Apron transfers the weight from the shoulders to the waist with the aid of a 6" wide elastic belt. Belts may be ordered to fit various sized individuals....
... Shielding's Back Relief Apron has ... transfers the weight from the ... the aid of a 6" ... shoulder strap keeps apron snug. ...
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Medicine Products: